Author(s): Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB
Abstract Share this page
Abstract Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.
This article was published in Nat Rev Drug Discov
and referenced in Journal of Proteomics & Bioinformatics